IP
APYX icon

Invenire Partners’s Apyx Medical APYX Stock Holding History

Invenire Partners’s Portfolio APYX Stock Details APYX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$4.25M Buy
945,711
+367,758
+64% +$2.63M 6.49% 4
2022
Q2 		$3.39M Buy
577,953
+166,954
+41% +$857K 4.5% 9
2022
Q1 		$2.68M Buy
410,999
+62,992
+18% +$620K 3.37% 17
2021
Q4 		$4.46M Buy
+348,007
New +$4.87M 4.72% 7

Other funds holding APYX

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
ACM
Archon Capital Management Seattle, Washington $177M AUM 108.05% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KLC
Kent Lake Capital Reno, Nevada $222M AUM 18.04% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
HKAM
Horizon Kinetics Asset Management New York $9.23B AUM 27.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Invenire Partners's APYX Position: Q3 2022 in Review

Invenire Partners increased its Apyx Medical (APYX) stake by 64% in Q3 2022, buying an estimated $2.63M and bringing the position to 945,711 shares worth $4.25M. The position accounts for 6.49% of the portfolio, ranked #4.

Invenire Partners first reported a position in APYX in Q4 2021 and has held it in 4 quarters since. The position peaked at $4.46M in Q4 2021. 54 funds tracked by Wall St. Rank hold APYX as of Q3 2022.

  • Invenire Partners held 945,711 shares of Apyx Medical worth $4.25M as of Q3 2022.
  • Invenire Partners bought 367,758 Apyx Medical shares in Q3 2022, an estimated $2.63M.
  • Apyx Medical made up 6.49% of Invenire Partners's portfolio in Q3 2022, its #4 holding.
  • Invenire Partners first reported a position in Apyx Medical in Q4 2021 and has held it in 4 quarters since.
  • Invenire Partners's Apyx Medical position peaked at $4.46M in Q4 2021.
  • 54 funds tracked by Wall St. Rank held Apyx Medical as of Q3 2022.

Based on Invenire Partners's 13F filing for Q3 2022, filed 14 Nov 2022.